openPR Logo
Press release

Second hospital in Izmir establishes VAD program for patients suffering from heart failure

06-25-2010 09:19 AM CET | Health & Medicine

Press release from: Berlin Heart GmbH

Second hospital in Izmir establishes VAD program for patients

Berlin, 24 June 2010. The Dokuz Eylul University Hospital in Izmir (Turkey) has just initiated their VAD (Ventricular Assist Device) program. This is the second hospital in Izmir, which offers patients suffering from end-stage heart failure a life-saving therapy.

The VAD systems are used for mechanical support of the heart function. In most cases these devices are implanted in order to bridge the waiting time for a matching donor heart in patients requiring heart transplantation. On rare occasions the mechanical support can lead to recovery of the heart and subsequent explantation of the system. For patients who cannot receive a heart transplantation, the device represents a life-saving alternative.

Just like the EGE University Hospital in Izmir, which is already running a really successful VAD program, the Dokuz Eylul University Hospital started the ventricular assist device program by implanting two consecutive BVAD cases. Prof. Öztekin Oto – the head of the VAD program at the Dokuz Eylul University Hospital - implanted his first blood pump “EXCOR®” in a 50-year-old patient suffering from dilative cardiomyopathy a few weeks ago. The day before the system was implanted, the patient´s condition deteriorated so rapidly, that Prof. Oto had to implant the EXCOR system which is manufactured by the German company Berlin Heart. A team from Berlin Heart came to provide professional support during and after the operation. The device now bridges the time until a matching donor heart becomes available. Prof. Oto recalls: “The implantation went very well, the patient meanwhile is mobilized and even switched to the mobile driving unit. He will be discharged home soon”. Dr. Stefan Thamasett, General Manager at Berlin Heart is happy about the great success the Turkish doctors are achieving. “In Turkey donor hearts are hardly available, the situation is even worse than in Germany. Therefore we are glad that our devices enable the surgeons to save the lives of those severely ill patients. At the beginning of this month the second EXCOR patient was implanted by Prof. Oto.
By the end of June the whole VAD team of the Dokuz Eylul University Hospital is invited to Berlin Heart in order to attend the Berlin Heart Academy. During the visit they will be trained on the pre- and post-operative patient management.

About EXCOR®
EXCOR is a paracorporeal ventricular assist device for patients of all age groups, from newborns to adults. It is used for short-, mid- and long-term cardiac support and can support failing hearts for any duration from a couple of days to several months and years. Since the first implantation in 1988 EXCOR has been implanted in more than 2.000 patients worldwide.
EXCOR® is currently under clinical investigation for pediatric use in USA. All other products are not FDA approved.

About Berlin Heart
Berlin Heart GmbH is the only company worldwide that develops, produces, and distributes implantable and external ventricular assist devices for patients of every age and body size. The company is the market leader in Germany and Europe.

Berlin Heart GmbH
Kerstin Unkel
Wiesenweg 10
12247 Berlin

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Second hospital in Izmir establishes VAD program for patients suffering from heart failure here

News-ID: 136327 • Views:

More Releases from Berlin Heart GmbH

Personnel changes in the management board of Berlin Heart GmbH
Personnel changes in the management board of Berlin Heart GmbH
As of October, 20th 2014 Mr. Sven-René Friedel and Dr. Ares K. Menon are appointed as new members of the management board. In addition to the finance and administration department, Mr. Friedel will be responsible for the departments Research & Development as well as Quality Management & Regulatory Affairs. Dr. Menon will be responsible for the departments Clinical Affairs & Clinical Science, Marketing & Sales, as well as Production. Each
1. Japanese EXCOR® Pediatric patient successfully transplanted
Berlin, 19.06.2013: The wait for a donor heart is over for the 1st Japanese patient treated with the EXCOR® Pediatric. On May 20th, 2013 the two-year-old girl was successfully transplanted at Morgan Stanley Childrens Hospital, New York Columbia Presbyterian Medical Center. According to the patient’s physicians, she tolerated the procedure well and is recovering as expected. In August 2012, for the first time in Japan’s history, it was possible
Successful air transport of the first Japanese baby with artificial heart to the …
Berlin, 07.03.2013: For the first time in the history of Japan the physicians Professor Murakami and Professor Ono of the University of Tokyo were able to save the life of an infant with severe heart failure with the help of a Berlin Heart EXCOR® Pediatric ventricular assist device in August 2012. The 21-month-old patient had fallen ill from a dilated cardiomyopathy and was successfully treated for almost six months at
Berlin Medical Technology Companies: State Secretary Nicolas Zimmer visits Berlin Heart
Berlin Medical Technology Companies: State Secretary Nicolas Zimmer visits Berli …
Berlin, 11. October 2012: The State Secretary of the Senate Department for Economics, Technology and Research, Nicolas Zimmer, visited Berlin Heart GmbH in Steglitz last month in order to get acquainted on location with the product line-up, range of application and operating mode of mid-sized Berlin companies. In conversation with the management of Berlin Heart, the present possibilities for therapy of cardiac insufficiency with the ventricular assist device were presented. In

All 5 Releases

More Releases for VAD

Ventricular Assist Devices (VAD) Market 2021: Global Industry Analysis Report to …
The global ventricular assist device market size was valued at USD 1.7 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 11% from 2021 to 2027. Ventricular assist devices, also known as VAD, are mechanical-assisted pumps used to support blood flow and heart function in people with impaired heart function. Ventricular assist devices help draw blood from the lower spaces of the heart and
Latest Trends in Implantable Ventricular Assist Devices (VAD) Market 2020-2025
This report also researches and evaluates the impact of Covid-19 outbreak on the Implantable Ventricular Assist Devices (VAD)industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Implantable Ventricular Assist Devices (VAD)and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.). Market Overview The Implantable Ventricular Assist Devices (VAD)market report provides a detailed analysis of global market size, regional
SPECTRAMI Announces VAD Partnership with Cato Networks for Germany
Tel Aviv, Israel, and Frankfurt, Germany – Sep. 11th, 2018 – Cato Networks, a leading provider of global, cloud-based SD-WAN with built-in network security stack, today announced it has signed a distribution agreement with SPECTRAMI for Germany. Cato Network enables organisations to establish a secure, global SD-WAN, delivered as a service, which is providing the core benefits of SD-WAN while enabling secure direct internet access, SLA-backed connectivity, and seamless extension of
TITUS Announces VAD Partnership with SPECTRAMI for Netherlands and DACH
Manchester, United Kingdom, and Frankfurt, Germany – Aug. 21th, 2018 – TITUS, a leading provider of data protection solutions, today announced it has signed a distribution agreement with SPECTRAMI for the Netherlands and DACH region. TITUS’ flexible software enables organisations to meet compliance regulations, standards, and frameworks such as the European Union’s General Data Protection Regulation (GDPR), Financial Market Supervisory Authority (FINMA) in Switzerland, ISO/IEC 27001:2013, NIST Cybersecurity Framework, and many
05-08-2017 | Health & Medicine
Ventricular Assist Devices (VAD) Market Assessment
Ventricular assist devices (VAD) are mechanical pumps used to support patients with a weakened heart or in case of heart failure to temporarily maintain heart function. The devices helps in re-establishing normal hemodynamics under conditions involving damaged ventricle. Increasing trend for sedentary lifestyle, rising obesity population globally, lifestyle changes and various other factors have resulted an increase in cardiovascular disorders. This rising prevalence across the globe has been a major
Global Ventricle Assist Device (VAD) Industry Analysis & Forecast Report 2016-20 …
Summary The Global Ventricle Assist Device (VAD) Industry Analysis & Forecast Report 2016-2021 is a professional and in-depth study on the current state of the Ventricle Assist Device (VAD) industry. The report analysis the global market of Ventricle Assist Device (VAD) by main manufactures and geographic regions. The report includes Ventricle Assist Device (VAD) definitions, product type, applications and industry chain structure, development trends, competitive landscape analysis, and key regions development